4Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): a Subgroup Analysis of GRIFFIN (AFT-29)
      Google Scholar   
Citation:
Blood vol 138 (Supplement 1) 2723
Meeting Instance:
ASH 2021
Year:
2021
Type:
Abstract
Sub type:
Oral
Funding:
AFT
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
JNJ  
Grants:
 
Corr. Author:
 
Authors:
                                                       
Networks:
ALLIANCE, CA043, CA136, CA249, FL065, IA018, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC007, LAPS-NY158, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, MUSC, NC002, NC042, NE003, NEWMEXICO, OR013   
Study
AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: